Novartis to Pay $245 Million in Settlement Over Antitrust Cases
29 Dezembro 2022 - 8:31AM
Dow Jones News
By Christian Moess Laursen
Novartis AG said Thursday that it would pay $245 million to end
antitrust cases accusing the Swiss pharmaceutical company of
anticompetitive conduct in the U.S.
The settlement relates to a 2011 license agreement between
Novartis and Par Pharmaceutical, Inc., in which Par delayed the
introduction of a generic drug that would compete with Novartis's
prescription drug Exforge, a blood pressure regulator, effectively
extending the life of Novartis's patents.
The settlement with direct purchasers, indirect purchasers, and
retailers is subject to court approval, Novartis said.
"Once final, this settlement will resolve all outstanding claims
related to this matter for Novartis," the company said.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
December 29, 2022 06:16 ET (11:16 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
